Joint Venture Mentis Care Aims to Transform Epilepsy Management with AI and Wearable Tech

SK Biopharmaceuticals Launches Joint Venture to Revolutionize Epilepsy Care

In a bold move towards digital healthcare, SK Biopharmaceuticals, Co., Ltd. announces the formation of a joint venture called Mentis Care, Inc. in collaboration with Eurofarma, a prominent Brazilian pharmaceutical company. The official launch, held on October 20, 2025, in Toronto, Canada, marks a pivotal step in SK Biopharmaceuticals' strategic expansion into innovative patient care solutions. This partnership aims to create an AI-driven platform specifically designed for the management of epilepsy, a central nervous system disorder that affects millions worldwide.

The joint venture focuses on developing an advanced platform that combines AI-powered electroencephalography (EEG) technology with wearable devices to enable accurate seizure detection and real-time monitoring. SK Biopharmaceuticals has been refining its expertise in this realm since 2018, laying the groundwork for this cutting-edge initiative. The Mentis Care platform will integrate real-time data collection with clinical decision support tools, providing healthcare professionals with critical insights to tailor personalized treatment plans for epilepsy patients. This comprehensive approach aims to improve patient outcomes significantly by enhancing the quality of care through timely interventions.

Located in the MaRS Discovery District, a leading innovation hub in Toronto, Mentis Care is poised to attract top talent and foster collaborations with academic institutions and industry partners. The joint venture plans to validate its AI algorithms through clinical trials, ensuring that the proposed solutions are based on solid scientific evidence. This initiative not only positions SK Biopharmaceuticals at the forefront of digital health innovations but also reflects its commitment to transforming epilepsy management through collaborative efforts and the integration of cutting-edge technology.

The establishment of Mentis Care highlights the growing trend within the healthcare sector towards digital solutions that enhance patient care. By harnessing the power of AI and wearable technologies, SK Biopharmaceuticals aims to set a new standard in the management of epilepsy, addressing unmet needs in the treatment landscape. This ambitious venture underscores the company's dedication to improving lives through innovative healthcare solutions.

As part of its broader strategy, SK Biopharmaceuticals continues to explore partnerships that enhance its capabilities in the digital health arena. The collaboration with Eurofarma not only expands its geographical reach but also enriches its technological expertise, paving the way for future advancements in the biopharmaceutical industry. With Mentis Care, the company looks to make a lasting impact on the lives of individuals affected by epilepsy.